Clinical Trial: Qingre Huatan Formula for the Prevention of Early Neurological Deterioration in Acute Ischemic Stroke

U.S., March 5 -- ClinicalTrials.gov registry received information related to the study (NCT06857487) titled 'Qingre Huatan Formula for the Prevention of Early Neurological Deterioration in Acute Ischemic Stroke' on Feb. 27.

Brief Summary: The purpose of this study is to assess the effectiveness and safety of Qingre Huatan formula versus placebo on preventing early neurological deterioration in patients with acute ischemic stroke within 48 hours after onset.

Study Start Date: April 15

Study Type: INTERVENTIONAL

Condition: Acute Ischemic Stroke

Intervention: DRUG: Qingre Huatan Formula

Qingre Huatan Formula, granules, 1 bag each time, twice a day, orally, continue for 10 days.

DRUG: Qingre Huatan Formula placebo

Qingre Huatan Formul...